Welcome to Mesothelioma.net - Turning Hope and Faith into Action.

Talc Pleurodesis Mesothelioma Patients Need Revised Imaging Approach

One of the most common treatment protocols used to ease symptoms for patients diagnosed with malignant mesothelioma is a procedure known as talc pleurodesis. The treatment addresses the discomfort and breathing difficulties caused by pleural effusions, a build-up of fluid around the lungs. This buildup causes tremendous pressure and makes it nearly impossible for patients to take a deep breath, and it is successfully treated by injecting a solution of talc into the space where the fluid appears. Unfortunately, though this fixes one problem and makes patients more comfortable, it also skews the results of PET scans, one of the most accurate ways to assess whether chemotherapy and other treatments have effectively stopped tumor progression. Now researchers have found a fix for this significant challenge.

Inaccurate PET/CT results caused by talc

According to Japanese researchers, mesothelioma patients who have had talc pleurodesis can benefit from  a small adjustment to the way that their PET/CT scan tests are administered. PET, or positron emission tomography, is one of the most accurate diagnostic tests for tumor growth, particularly when it is combined with CT (computed tomography). When PET/CT is administered, patients get an injection of a material called FDG (fluorodeoxyglucose) that highlights tumor cells, making them more visible to physicians. But when a patient has had talc pleurodesis, the FDG can collect in the areas where the talc has been inserted, giving those looking at the test results an inaccurate picture of the patients’ condition.

Scientists recommend use of different tracer in PET/CT following talc pleurodesis

In response to this finding, the researchers tested a different methodology on mesothelioma patients who had undergone talc pleurodesis, and they found it delivered much more accurate results. Rather than injecting the patients with FDG before the scan, the researchers used a material called Choline C-11 which does not get absorbed by the inserted talc. Instead, the choline C-11 only gets absorbed by true cancer cells, thus giving physicians a much better sense of the impact of the treatments they have administered. As a result, the researchers are suggesting that imaging studies conducted on patients who have already had talc pleurodesis adopt the use of Choline C-11 as a tracer.

Making necessary adjustments is the new normal for those diagnosed with malignant mesothelioma. For information on other options to make your life easier, contact the Patient Advocates at Mesothelioma.net at 1-800-692-8608.

Terri Oppenheimer

Terri Oppenheimer is an experienced blog writer, editor, and proofreader. She graduated from the College of William and Mary with a degree in English. She specializes in providing content for websites and finds tremendous enjoyment in the things she learns while doing her research. Her specific areas of expertise include health, medical research, and law.

Get Your FREE Resources Sent Overnight

  • New treatment options
  • Veterans benefits & claims
  • $30 Billion asbestos trust fund information

– Or Call –

Site Navigation

Where can I

Get Additional Help?

For over 20 years, we’ve provided the best FREE resources to mesothelioma patients and loved ones. Our resources include information on the leading treatment options and best doctors in your area; lessons learned from survivors; claims and benefits specifically for Veterans; and how to access your share of billions of dollars in trust fund money.

Get Your FREE Resources Sent Overnight

  • New Treatment Options
  • Veteran's Benefits & Claims
  • $30 Billion Asbestos Trust Fund Information

– Or Call –

We are here to help you


If you've been diagnosed with asbestos-related cancer, contact us at 1-800-692-8608 to find out if you are eligible to receive compensation. You can also fill out the form above to receive FREE information.

$30 Billion Asbestos Trusts
Get Started